Next Article in Journal
Therapeutic Agents with AHR Inhibiting and NRF2 Activating Activity for Managing Chloracne
Next Article in Special Issue
High Vitamin C Status Is Associated with Elevated Mood in Male Tertiary Students
Previous Article in Journal
Isoprostanoids in Clinical and Experimental Neurological Disease Models
Previous Article in Special Issue
Spatial Memory Dysfunction Induced by Vitamin C Deficiency Is Associated with Changes in Monoaminergic Neurotransmitters and Aberrant Synapse Formation
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessReview
Antioxidants 2018, 7(7), 89; https://doi.org/10.3390/antiox7070089

Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials

1
National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Clinical Nutrition Section, Bethesda, MD 20892, USA
2
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
*
Author to whom correspondence should be addressed.
Received: 10 May 2018 / Revised: 3 July 2018 / Accepted: 6 July 2018 / Published: 12 July 2018
(This article belongs to the Special Issue Vitamin C: Current Concepts in Human Physiology)
View Full-Text   |   Download PDF [1023 KB, uploaded 12 July 2018]   |  

Abstract

Background: Ascorbate (vitamin C) has been evaluated as a potential treatment for cancer as an independent agent and in combination with standard chemotherapies. This review assesses the evidence for safety and clinical effectiveness of intravenous (IV) ascorbate in treating various types of cancer. Methods: Single arm and randomized Phase I/II trials were included in this review. The PubMed, MEDLINE, and Cochrane databases were searched. Results were screened by three of the authors (GN, RP, and CJP) to determine if they met inclusion criteria, and then summarized using a narrative approach. Results: A total of 23 trials involving 385 patients met the inclusion criteria. Only one trial, in ovarian cancer, randomized patients to receive vitamin C or standard of care (chemotherapy). That trial reported an 8.75 month increase in progression-free survival (PFS) and an improved trend in overall survival (OS) in the vitamin C treated arm. Conclusion: Overall, vitamin C has been shown to be safe in nearly all patient populations, alone and in combination with chemotherapies. The promising results support the need for randomized placebo-controlled trials such as the ongoing placebo-controlled trials of vitamin C and chemotherapy in prostate cancer. View Full-Text
Keywords: intravenous; ascorbate; vitamin C; clinical trials; cancer; patients intravenous; ascorbate; vitamin C; clinical trials; cancer; patients
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Nauman, G.; Gray, J.C.; Parkinson, R.; Levine, M.; Paller, C.J. Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials. Antioxidants 2018, 7, 89.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antioxidants EISSN 2076-3921 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top